Drugs / Atrovent Respimat (20 mcg)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00400153 | Nov 2006 → Apr 2008 | chronic obstructive pulmonary disease | Boehringer Ingelheim | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Atrovent Respimat (20 mcg) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00400153 ↗ |
| Route | Inhaled | “ipratropium bromide (20mcg) Respimat inhaler” PMID 20172704 ↗ Feb 2010 |